Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod (Formerly Called OK-101) Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

NCT07838506 is registered in ClinicalTrials.gov with Okyo Pharma Ltd as lead sponsor.

NCT NCT07838506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07838506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod (Formerly Called OK-101) Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).
Lead sponsor
Okyo Pharma Ltd
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
October 31, 2027
Enrollment
111 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuropathic corneal pain